{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:19:33Z","timestamp":1778703573428,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Given the rarity and elderly onset of immune checkpoint inhibitor (ICI)-induced type 1 diabetes (ICI-T1DM), cases leading to delivery are rare.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>To our knowledge, this is the first case report of childbirth in a patient with ICI-T1DM after cancer survival. A 32-year-old woman was started on Nivolumab for metastatic parotid cancers one year after total parotidectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>The patient developed ICI-T1DM after 43 cycles and started multiple daily insulin therapy and self-monitoring of blood glucose. Complete response was maintained for 2 years by nivolumab, and she finished nivolumab in 77 cycles to attempt pregnancy. During the follow-up period, she began using a sensor-augmented pump (SAP). She had undetectable serum and urinary C-peptide when she started SAP. Her HbA1c level decreased from 7.8 to 6.6% without increasing hypoglycemia in one year. The patient remained in complete response after ICI discontinuation, and embryo transfer was initiated. Pregnancy was confirmed after a second embryo transfer (21 months after ICI discontinuation). At 36 weeks and 6 days, an emergency cesarean section was performed due to the onset of preeclampsia. The baby had hypospadias and bifid scrotum but no other complications or neonatal intensive care unit admission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Because ICI discontinuation and ICI-T1DM carry risks for the patient and child, the decision regarding pregnancy warrants careful consideration. Diabetologists should collaborate with patients and other clinical departments to develop a treatment plan for childbirth.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-024-03780-w","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T07:02:43Z","timestamp":1710831763000},"page":"593-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report"],"prefix":"10.1007","volume":"85","author":[{"given":"Keiji","family":"Sugai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"3780_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"S. Bagchi, R. Yuan, E.G. Engleman, Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev. Pathol. 16, 223\u2013249 (2021). https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741","journal-title":"Annu Rev. Pathol."},{"issue":"5","key":"3780_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100276","volume":"6","author":"M Garutti","year":"2021","unstructured":"M. Garutti, M. Lambertini, F. Puglisi, Checkpoint inhibitors, fertility, pregnancy, and sexual life: A systematic review. ESMO Open 6(5), 100276 (2021). https:\/\/doi.org\/10.1016\/j.esmoop.2021.100276","journal-title":"ESMO Open"},{"key":"3780_CR3","unstructured":"Opdivo - Ema Technical Sheet. [cited 2024 2.14]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf"},{"issue":"5","key":"3780_CR4","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2337\/dc21-2213","volume":"45","author":"X Chen","year":"2022","unstructured":"X. Chen, A.H. Affinati, Y. Lee, A.F. Turcu, N.L. Henry, E. Schiopu et al. Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care 45(5), 1170\u20131176 (2022). https:\/\/doi.org\/10.2337\/dc21-2213","journal-title":"Diabetes Care"},{"issue":"7","key":"3780_CR5","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.2337\/dc20-0459","volume":"43","author":"J Liu","year":"2020","unstructured":"J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, Y. Huang et al. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015\u20132019. Diabetes Care 43(7), e79\u2013e80 (2020). https:\/\/doi.org\/10.2337\/dc20-0459","journal-title":"Diabetes Care"},{"key":"3780_CR6","doi-asserted-by":"publisher","unstructured":"O. Fukuoka, Y. Saito, T. Mukai, T. Hayashi, K. Yamamura, T. Sakai et al. Efficacy of chemotherapy after immune checkpoint inhibitor discontinuation in head and neck cancer. Laryngoscope (2023). https:\/\/doi.org\/10.1002\/lary.30851","DOI":"10.1002\/lary.30851"},{"issue":"25","key":"3780_CR7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMra1712502","volume":"379","author":"CL Shapiro","year":"2018","unstructured":"C.L. Shapiro, Cancer survivorship. N. Engl. J. Med 379(25), 2438\u20132450 (2018). https:\/\/doi.org\/10.1056\/NEJMra1712502","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"3780_CR8","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/dc22-2202","volume":"46","author":"L Wu","year":"2023","unstructured":"L. Wu, V. Tsang, A.M. Menzies, S.C. Sasson, M.S. Carlino, D.A. Brown et al. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (Ciadm): A systematic review and delineation from type 1 diabetes. Diabetes Care 46(6), 1292\u20131299 (2023). https:\/\/doi.org\/10.2337\/dc22-2202","journal-title":"Diabetes Care"},{"key":"3780_CR9","doi-asserted-by":"publisher","unstructured":"N. Hara, H. Suwanai, F. Yakou, K. Ishii, H. Iwasaki, H. Abe et al. Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study. Endocrine (2023). https:\/\/doi.org\/10.1007\/s12020-023-03394-8","DOI":"10.1007\/s12020-023-03394-8"},{"issue":"1","key":"3780_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2337\/dc14-1755","volume":"38","author":"MJ Maresh","year":"2015","unstructured":"M.J. Maresh, V.A. Holmes, C.C. Patterson, I.S. Young, D.W. Pearson, J.D. Walker et al. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care 38(1), 34\u201342 (2015). https:\/\/doi.org\/10.2337\/dc14-1755","journal-title":"Diabetes Care"},{"issue":"12","key":"3780_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1089\/dia.2021.0112","volume":"23","author":"G O\u2019Malley","year":"2021","unstructured":"G. O\u2019Malley, B. Ozaslan, C.J. Levy, K. Castorino, D. Desjardins, C. Levister et al. Longitudinal observation of insulin use and glucose sensor metrics in pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps: the Lois-P study. Diabetes Technol. Ther. 23(12), 807\u2013817 (2021). https:\/\/doi.org\/10.1089\/dia.2021.0112","journal-title":"Diabetes Technol. Ther."},{"issue":"6","key":"3780_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.2040-1124.2010.00059.x","volume":"1","author":"S Shibasaki","year":"2010","unstructured":"S. Shibasaki, A. Imagawa, J. Terasaki, T. Hanafusa, Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes. J. Diabetes Investig. 1(6), 283\u2013285 (2010). https:\/\/doi.org\/10.1111\/j.2040-1124.2010.00059.x","journal-title":"J. Diabetes Investig."},{"issue":"18","key":"3780_CR13","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1001\/jama.2019.4981","volume":"321","author":"AS Alexopoulos","year":"2019","unstructured":"A.S. Alexopoulos, R. Blair, A.L. Peters, Management of preexisting diabetes in pregnancy: a review. JAMA 321(18), 1811\u20131819 (2019). https:\/\/doi.org\/10.1001\/jama.2019.4981","journal-title":"JAMA"},{"issue":"1","key":"3780_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-022-04906-6","volume":"22","author":"Y Wang","year":"2022","unstructured":"Y. Wang, L. Wang, Z. Yang, F. Chen, Z. Liu, Z. Tang, Association between perinatal factors and hypospadias in newborns: a retrospective case-control study of 42,244 male infants. BMC Pregnancy Childbirth 22(1), 579 (2022). https:\/\/doi.org\/10.1186\/s12884-022-04906-6","journal-title":"BMC Pregnancy Childbirth"},{"issue":"5","key":"3780_CR15","doi-asserted-by":"publisher","first-page":"484 e1- e4","DOI":"10.1016\/j.jpurol.2017.02.022","volume":"13","author":"Y Epelboym","year":"2017","unstructured":"Y. Epelboym, C. Estrada, J. Estroff, Ultrasound diagnosis of fetal hypospadias: accuracy and outcomes. J. Pediatr. Urol. 13(5), 484 e1- e4 (2017). https:\/\/doi.org\/10.1016\/j.jpurol.2017.02.022.","journal-title":"J. Pediatr. Urol."},{"issue":"3","key":"3780_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-3016.2007.00809.x","volume":"21","author":"SL Carmichael","year":"2007","unstructured":"S.L. Carmichael, G.M. Shaw, C. Laurent, R.S. Olney, E.J. Lammer, National birth defects prevention S. Maternal reproductive and demographic characteristics as risk factors for hypospadias. Paediatr. Perinat. Epidemiol. 21(3), 210\u2013218 (2007). https:\/\/doi.org\/10.1111\/j.1365-3016.2007.00809.x","journal-title":"Paediatr. Perinat. Epidemiol."},{"issue":"12","key":"3780_CR17","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.2337\/dc20-0261","volume":"43","author":"Y Wu","year":"2020","unstructured":"Y. Wu, B. Liu, Y. Sun, Y. Du, M.K. Santillan, D.A. Santillan et al. Association of maternal prepregnancy diabetes and gestational diabetes mellitus with congenital anomalies of the newborn. Diabetes Care 43(12), 2983\u20132990 (2020). https:\/\/doi.org\/10.2337\/dc20-0261","journal-title":"Diabetes Care"},{"issue":"5","key":"3780_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100262","volume":"6","author":"A Andrikopoulou","year":"2021","unstructured":"A. Andrikopoulou, A.M. Korakiti, K. Apostolidou, M.A. Dimopoulos, F. Zagouri, Immune checkpoint inhibitor administration during pregnancy: a case series. ESMO Open 6(5), 100262 (2021). https:\/\/doi.org\/10.1016\/j.esmoop.2021.100262","journal-title":"ESMO Open"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03780-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T11:55:50Z","timestamp":1722426950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03780-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3780"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03780-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.T. received speakers bureaus from Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company. R.S. received honoraria, subsidies, and donations from Novo Nordisk Inc., Sanofi K.K., Sumitomo Pharma Co., Ltd., Astellas Pharma Inc., Kowa Co., Ltd., MSD K.K., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co., Teijin Pharma, Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo co., Ltd., Sanwa Kagaku Kenkyusho, Ltd., Takeda Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim Co. The remaining authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent for publication was obtained from the patient and legal guardian of the minor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}